Skip to content

A clinical study to assess the efficacy of a probiotic supplement for women to reduce depression and anxiety symptoms after giving birth

A randomized double blind controlled clinical study to assess the effect of treatment with a probiotic supplement targeted to women after pregnancy, to reduce postpartum symptoms of depression and anxiety

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN99047904
Enrollment
200
Registered
2021-11-24
Start date
2020-07-21
Completion date
Unknown
Last updated
2024-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of post-partum depression and mastitis in healthy new mothers and reduction of excessive crying in the newborns. Mental and Behavioural Disorders

Interventions

2 groups of 100 subjects were invited to orally take one capsule/day for 90 days, starting from delivery, as follows: one group (A) used the complete active treatment (Probiotics mix + multivitamin fo

Sponsors

Roelmi HPC
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Healthy pregnant female subjects after their delivery

Exclusion criteria

Exclusion criteria: 1. Subjects who do not meet the inclusion criteria 2. Subjects considered as not adequate to participate to the study by the investigator 3. Subjects with known or suspected sensitization to one or more test formulation ingredients 4. Adult protected by law (under control or hospitalized in public or private institutions for reasons other than research, or incarcerated) 5. Subjects not able to communicate or cooperate with the investigator for problems related to language, mental retardation or impaired brain function 6. Suffering from other psychiatric disorders such as schizophrenia, other psychotic disorders, bipolar disorder or substance use disorder 7. Serious physical illnesses or mental disorders due to a general medical condition which are judged by the investigator to render unsafe 8. A significant risk of infanticide according to the investigator assessment 9. Herbal remedies or psychotropic drugs that are intended for depression are taken within the last 2 weeks prior to baseline or during the study 10. Receiving counseling or psychological therapies at baseline or during the study 11. Participation in any clinical trial within the previous 3 months prior to baseline

Design outcomes

Primary

MeasureTime frame
Depression and anxiety symptoms and post-natal stress measured using the Edinburgh Postnatal Depression Scale (EPDS) after 45 and 90 days

Secondary

MeasureTime frame
1. Baby's crying, measured using Breastfeeding Self Efficacy Scale Short Form and Children Cry Questionnaires after 45 and 90 days. 2. Mastitis measured using Breastfeeding Quality Questionnaire after 45 and 90 days

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026